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The need for prophylactic anticoagulation f prevent embolism
before direct current cardloverstan Is performed For alrial fibril-
lation or alrial flutter is controversial . To examine this issue
further, a retrocpw"ive review was undertaken to assess the
incidence of embolic complications after cardioversion, The re'
view involved 454 elective direct current cardioversion per-
formed for atrial fibrillation or atria) flutter over a 7 year period .
The incidence rate of embolle mmplicatons was 1 .3250 (six
patients); the eomplica!ions ranged from minor visual dislurv
helices to a fatal cerehrnvasculat event . All six patients had alrial
fibrillation, and none had been on anticoagulant therapy (p =
0.026), The en .oOvn ar nrr,nl fibrillation was < I week in five of
the six patterns who had embolic complications .
Baseline characteristics of patients with a posteardioversion
Atrial fibrillation increases the risk for ischemic stroke by a
factor of 5 over a lifetime. It has been estimated that one
third of ali patients with alrial fibrillation will eventually have
a cerebrovascular accident ID, Atrial fibrillation has aicz
been implicated in up to 37% of asymptomatic cerebral
infarcts diagnosed by computed tomographic scans (2-4).
Because of the incidence of stroke, some investigators (5-7)
recommend that certain subgroups of patients with atnol
fibrillation receive long-term anticoagulant therapy. Al-
though the risk of embolism may be decreased by anticoag-
ulant therapy, there is a lack of consensus regarding the need
for such therapy before direct current cardioversion is
performed in patients with atriat fibrillation or atria) flutter
(8-10). To further assess the need for anticoagulation in the
setting of elective cardioversion we retrospectively reviewed
the results of 628
consecutive cardioversions
.
Methods
Study patients. Adult patients undergoing elective direct
current cardioversion at our institution for atria) fibrillation
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embolic event are compared with these of patkats who did rot
have an embafie event. There was no difference In the prevalence
of hypertension, diabetes mi llitus or prior stroke between the two
groups, and there was no
difference in the number of patients
who
were postoperative or had poor kit ventricular functka . Left
atria) sire was similar between the two groups . No Pattern In the
embolic group had valvular disease.
No patient with initial Butter badan embolle event regardless of
anticoagulant status; therefore, anticoagulation is act recum .
mended fur patients with acrid flutter undergoing cardinversion .
Prophylactic ladcmguktion is pivotal in patients undergoing
elective direct emrem cardioversion for aeriul fibrillation, even
those with acid fibrillation of <I week's duration .
(J Am Calf Cordial 1992;191851 5)
or atrial flutter (of at least 48 h duration) between January I,
1983 and June 30, 1990 were included. Our analysis excluded
unsuccessful cardioversions, because tl c?"rerslun
m nor-
mal sinus rhythm is
the presumed risk factor for embolic
events, We excluded 90 cardioversions on this basis, along
with 51 in which atria[ fibrillation or atria) flutter was present
for <48 h and 33 cardioversion with indeterminate antico-
agulant stains . There were 628 procedures performed in the
study per'od add 454 (in 428 patients) were subsequently
reviewed. In I77 cardioversions (40.7%) ; the patient was
inking anticoagulant medication (Coumadin in 98 .3%) . This
report summaries the characteristics of the patients under-
going direct current Cardioversion and the embolic phenom-
ena that occurred as a direct consequence of the procedure .
Cardioversion. All procedures were carried out in a fully
equipped cardiac catheterization or electrophysiology labo-
ratory
with emergency equipment available . Digitalis prep •
orations were withheld the morning of the procedure . and
The patient was fasting. Intravenous sedation (usually a bolus
irijection of Brevital 0.5 mg/kg body weight) was given, and
a synchronized, direct current shock was administered to
restore sinus rhythm
. Pre- and postcardioversion rhythm
strips were available to 'crlfy the presence of atria) fihritla-
tion or atria) flutter before the procedure and subsequent
sinus rhythm after cardioversion. Cardioversioos performed
in the patients room or the intensive care unit for the
purpose of terminating hemodynamicalty unstable atria] fi-
brillation or atrial flutter were excluded .
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Data analysis
. The medical record was reviewed for
demographic characteristics and underlying diseases (hyper-
tension, diabetes mellitus or prior cercbrovascular accident
) .
In addition, echocardiographically documented left atrial
size, as well as left ventricular function (documented by
cathelerization or echocardiographic analysis) . was noted .
The duration of the specific rhythm disturbance was ana-
lyzed . If the patient had recently undergone open heart
surgery. the nature of the procedure was noted . and for
valvular surgery, the position and type of valve were iden-
tified . Anticoagulant medication was recorded and Inborn-
Tory variables were checked to confirm therapeutic activity .
A prothrombin time >15 s (L5 times the lower limit of the
10-s control value in out laboratory) or an activated partial
thromboplastin time of 50 s (twice the lower control limit)
was considered therapeutic.
F.11-lip . All patients were followed up for evidence of
embolism for at least 2 weeks, and postoperative patients
were followed up until their 6-week postoperative visit .
Embolic events were coded as having occurred in the
cerebral, pulmonary or peripheral circulation and were doc-
umented by computed tomogrtphy . ventilation-perfusion
scanning or angiography .
Statistics. All values are given as the mean values
I SD . Group comparisons of categoric variables were made
by using the chi-square or Fisher exact test, as appropriate .
Continuous variables were compared by using the Student t
test. A p value <11.05 was considered significant .
Baseline characteristics, The predominant rhythm distur-
bance requiring cardioversion was atrial fibrillation (atrial
fibrillation in 72 .8%. atrial flutter in 27
.2%). The majority
168
.671 of the patients with atrial fibrillation were male, and
the average age was 64 ± 9.7 years (range 21 to 88) .
Concomitant hypertension was present in 36
.6% of patients,
diabetes mellitus in 14 .7% .a history of prior cercbrova5cular
accident in 10 .7%a . There were 206 patients (67 .3%) with
postoperative atrial fibrillation at the time of cardioversion .
These baseline characteristics are summarized further in
Figure I . There were no statistical differences between the
characteristics of patients who were or were not receiving
ant)congulant therapy,
In the patients with direct current cardioversion for atrial
fibrifation, the duration of arrhyduoia ranged from 48 h to 7
years. The duration of atrial fibrillation was <8 days in
43-'7,-'/
of
cardioversions . 8 to 30 days in 29S%, >30 days but
<I year in 25!9%, and > 1 year in 0.9% of cardioversions
;Fig. 2)
. Prosthetic valves had been implanted in 85 patients
'27 .7%) ; the prosthesis was in the mitral valve position in 44
patients, the aortic valve position in 32 and in both positions
in 9 .
E<'6liographir data
were available for 63 .3% of
patients undergoing direct current cardioversion for atrial
fibrillation . The average left atrial size was 49 ± 8 .2 mm
(range 27 to 72)
. The left atrial size did not correlate with the
duration of arrhythmia ; in patients with atria] fibrillation for
<30 days the average left atrial size was 49 `- 8.2 mm and in
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Figure 1, Baseline characteristics of the patients with atrial fibrilla-
tion . AC = with anticoagulant therapy ; CVA - cerebrovascular
accident : NO AC - without anticoagulant therapy ; natural -
patients who did not have atrial fibrillation related to an operative
intervention ; POSTOP = postoperative .
those with atrial fibrillation for >30 days the average size
was 50 ± 8 mm .
Assrcsntettt ofleft venrrirnlarfmction
was available for
96.1% of patients ; 70 .1% were characterized as having
normal function or mild dysfunction . Of the remaining
patients . 19.7% had moderate and 10.2% had severe left
ventricular dysfunction .
Results
Atria) fibrillation . There were 454 cardioversions per-
formed to treat atria] fibrillation or
atria[
flutter. Embolic
vents occurred in 6 of 179 cardioversions for atrial fibrilla-
tion in the absence of anticoagulant therapy . No embolic
events occurred in the 153 cardioversions for atrial fibrilla-
lion in patients who were taking an anticoagulant agent . This
difference was statistically significant (p = 0 .026). Anticoag-
ulation was used in 47% of patients without embolism and in
Figure 2 . Duration of atrial fibrillation. Abbreviations as in Fig-
ure I .
none of the six patients with embolism (p = Rfi2)- The
consequences of Ihese embolic events ranged from minor
visual disturbances to a fatal cerebrovascular embolus
. In
the group of six patients with embolism, four had hyperten .
,ion and one patient had a history of prior cerebrovascular
accident . No significant bleeding episodes related to antico-
agulatinn were noted in the study group
. The average
duration ofalrial fibrillation in the six patients with embolism
was 6 ± 4 days (range 3 to 19) and two patients (33'7cl were
postoperative. The average left atrial size was 44
.
5 mm
;
and left ventricular function was impaired to a moderate or
severe degree in four (67%) of the six (Table 1) .
Cardioversion with aruiroagulaar therapy. There were
153 cardioversion performed on patients with laboratory
confirmation of therapeutic anticoagulation . Postoperative
atrial fibrillation was present in 11)1 cases ; the remaining 5;
cardioversion were performed for naturally occurring atria)
fibrillation (that is, atrial fibrillation that did not occur in the
postoperative period) . Nineteen percent of the cardlover-
sions were performed in patients who had been receiving
anticoagulant therapy for >2 weeks before cardioversion (at[
except one patient were in the cohort with naturally occur-
ring atrial fibrillation) . The duration of anticoagulation did
not appear to affect the incidence of embolic events.
Cardioversion without anricoagulanr therapy. There
were 179 cardioversions perforated in patients for atria[
fibrillation who were not receiving anticoagulant therapy :
115 were postoperative and 64 were in the group with
naturally occurring atrial fibrillation. Two rises of embalism
occurred in the postoperative group without anticoagulant
therapy (incidence rate 1 .790) and four occurred in the
natural atrial fibrillation group without anticoagulant therapy
(incidence rate 6
.2%% ; p
= NS)
. These results are summa-
rized in the flow diagram in Figure 3 .
Atria] flutter. We also analyzed data from cardioversion
in 122 patients with atrial flutter, Similar m others (8,11), we
found no embolic events in this group, regardless of antico-
agulant status (2h% with and 74% without anticoagulant
Therapy)_ The number of patients with atrial flutter in our
study may be too small to fully detect a low frequency event
such as postcardioversion embolism . Our data support the
current practice of not giving anticoagulant therapy to pa-
tients with atrial flutter who undergo cardioversion .
AF - slant SbIiILianI F - femste
. LV -
Ld :annicutur . M = r, M.?o.up = p,nrnrrror ,e:'I - rouses.
Discussion
Synchronized electrical cardioversion for the termination
of both atrial and ventricular tachyarrhythmias in a large
series of patients was first reported by Lown (12) in 1%7 .
The most devastating complication of this procedure is
systemic embolization, which has been estimated to occur in
up to 792 of patients (I3) . The atria) arrhythmia most likely to
be associated with postcardioversion embolism is airiat
fibrillation (5,11) . a finding further supported by our results.
No patient in our series who underwent cardioversion for
atrial flutter had an embolic event .
Mechanism ofembelration . The ntechanismofemboliza-
tion in atrial fibrillation appears to be complex . Researchers
(6) have documented increased cerebral
blood flow
after
conversion from atrial fibrillation to normal sinus rhythm,
which predisposes to cerebral embolism in the distribution of
the middle cerebral artery . An intrinsic but unidentified
property of atrial fibrillation may lead to ahnormalitics in
clu)ting function, which may contribute to the incidence of
emholieation after cardioversion (14). Atrial fibrillation is
associated with increased levels of airial natrturetic peptide
and an increase in hematocrit (15) . These changes may
flint, 1 . lInus diagram !hos5ittg be analysis of 521 eardierensiuts
and the rat ents with subsequent embolism. AC = with anticoagu-
lant therapy : AF = atrial fibrillation;AFi. = arrant flutter: DCC =
direct-current cardioversion : NAT = natural alriat fihrillatiost Isee
text)
; noAC = without amicoagulane therapy; POSTOP = postop-
erative .
Cardioversion flow diagram
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Table I • Charaelerislics of Six Patients With an Embo'ic Evcat
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account for the increase in stroke with chronic atria) fibril-
lation.
One of the suggested mechanisms of embolism is the
formation during atrial fibrillation of a clot that is expelled
with the sudden resumption of mechanical atrial systole.
Obarski et al. (16) detected a spontaneous echo contrast,
consistent with blood stasis, during transesophageal echo-
cardiography in a patient with atrial fibrillation, enlarged left
atrium and a normal mitral valve . The study was repeated
after the patient was in sinus rhythm . The echo contrast
(residual stasis) was localized to the left atrial appendage,
whereas the remainder of the left atrium was clear . Obarski
et al
. (16) theorized that this residual blood stasis may
account forembolic events several days after sinus rhythm is
restored. However, this residual stasis does not account for
the lower incidence of embolism with paroxysms of atrial
fibrillation compared with the incidence with chronic atrial
fibrillation . Short paroxysms may not allow the hormonal
changes that result in clot formation to occur .
Incidence of emholizatimt . Although it has been suggested
that patients with atrial fibrillation should receive anticoag-
uiant therapy before undergoing direct current cardioversion
(11,12), there is a lack of consensus on such treatment. Data
arc sparse on the incidence of embolism after cardioversion
for specific arrhythmias. In a 1967 review, Lown (12) exam-
ined 456 cardioversion attempts and reported a 1 .2% inci-
dence rate of embolization . No patient received anticoagu-
lant therapy at the time of the procedure . In 1969,
Bjerkelund and Orning (9) reported the effect of anticoagu-
lation on the rate of stroke after cardioversion in a nonran-
domized population of 437 patients . They reported that
cardioversion without anticoagulation resulted in a 5 .3%
incidence rate of embolism compared with a rate of 0 .8%
with anticoagulation (p = 0 .016) . Although the study was
nonrandomized, the results are important as the patients
receiving anticoagulant therapy were at higher risk for
embolization because of their underlying rheumatic heart
disease, congestive heart failure and history of prior embolic
events . Unfortunately, because the patients were receiving
long-term anticoagulant therapy, the effect of prophylactic
anticoagulation before cardioversion cannot be addressed
.
Also, subgroups were not analyzed by rhythm (atria] fibril-
lation or atrial flutter), which is reported to be an indepen-
dent risk factor for embolic phenomena after cardioversion
(11,17,18) .
More recently, Mancini and Weinberg (19) reviewed the
data from the University of Michigan over a 10-year period
and analyzed embolic events after cardioversion for atrial
fibrillation . They found no events in the group with antico-
agulant
therapy, whereas 7% of the group without such
therapy had embolic complications
. Although the numbers
are small, the results support well managed, short-term
anticoagulant treatment in high risk patients (defined by the
authors as patients >55 years old with coronary artery
disease, cardiomyopathy or hypertension and with a dura-
tion of atrial fibrillation of >I year) .
JACC Vol . 19, No. 4
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Although our 1 .32% incidence rate of emboli : events
after cardioversion for atrial fibrillation is similar to that of
other reports (20-22), there may be a subset of patients who
are at higher risk for embolic events : patients with naturally
occurring atrial fibrillation who do nut receive anticoagulant
therapy. These patients had an incidence of embolism that
was nearly four times that of the postoperative group with-
out anticoagulant therapy . Although this difference in inci-
dence did not achieve statistical significance, further inves-
tigation in a larger series of patients seems warranted .
Duration of anticoagulation . Atria) fibrillation of long
duration is a well documented risk factor for stroke
(1). It
has been recommended (8,11) that patients with atrial fibril-
lation of short duration (I 1 week) do not need anticoagula-
tion before undergoing cardioversion . In our patients who
had an embolic event, the duration of axial fibrillation
ranged from 3 to 19 days (average 6
.
4), with five of the six
patients having atrial fibrillation for e I week . Direct current
cardioversion appeared to be hazardous in our patients with
atria] fibrillation of short duration who were not receiving
anticoagulant therapy. Our results suggest that low dose
anticoagulation with a prothrombin time >15 s was protec-
tive against embolic events .
Most cases of embolism have been reported to occur
within hours to a few days of cardioversion (9,10) . Theoret-
ically, however, embolism can occur several weeks after
electrical conversion when mechanical atrial activity re-
sumes (23) . While this theoretical risk of embolism remains
for up to 3 weeks (24,25), all of the embolic events in our
patients occurred within 7 days after c ardioversion. it is
therefore unclear how long anticoagulant therapy should be
continued after successful conversion to sinus rhythm. Be-
cause of the retrospective nature of our data, the length of
time that anticoagulation was continued after cardioversion
is not well documented . We cannot conclude that anticoag-
ulation at the moment of cardioversion, without its continu-
atiun, will prevent a delayed embolism . Manning et al . (23)
followed the reccvery of atria] mechanical function in 21
patients over 3 months with serial Doppler echocardio-
graphic evaluations . They found that peak A wave velocity
and percent of atrial contribution to left ventricular filling did
not return to normal until 3 weeks after cardioversion in
patients who maintained sinus rhythm . Continued anticoag-
ulation for several weeks is net likely to result in significant
bleeding complications (26) and probably should be main-
tained until mechanical atrial systole resumes .
Our data raise a number of important issues . Should a
patient with atrial fibrillation of >2 days' duration receive
anticoagulant therapy before elective direct current cardio-
version? Is the anticoagulant of choice Coumadin . or is
heparin adequate therapy? We believe that further investi-
gation with randomized, prospective trials should be under-
taken to answer these important clinical concerns .
Limitations of study . The limitations of our study are
those inherent in any retrospective review. There was no
randomization of treatment arms for anticoagulation, and we
IACC Vol . 19
. No . 4
March 15 . 1992:851-5
were unable to identify specific high risk subsets that would
benefit from anticoagulant therapy. However, despite these
limitations
. all the errrbulic events came from the group
without anticoagulant therapy .
Cenelusions. In our series . atrial Burner was never asst,
eiated with an embolic event and
we
du not recommend
Tontine anticoagulation in these patients . Our results
strongly support the use of anticoagulant treatment in pa-
tients with atrial fibrillation of at least 4g-h duration who are
undergoing elective synchronized direct current Cardiovef
.
siou. .It seems prudent to continue anticoagulation until
mechanical atrial systole resumes. Although others 19.13 210
have reported a similar risk of embolization with chemical
cardioversion .
ear study
was not designed
to examine this
risk. Further research
is needec for those undergoing ear-
dioversion with antiarfhylhmtc agents,
as
anticoagulation
may be appropriate based on theoretical considerations .
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